September 21, 2017
Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia
A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on models derived from solid tumors. But these highly predictive preclinical models can also be developed from blood cancer.
LEARN MORE
September 19, 2017
Beginners Guide: Humanized Drug Target Immuno-Oncology Models
Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ...
LEARN MORE
September 12, 2017
CD137: An Important Target in T Cell Co-Stimulation
Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell ...
LEARN MORE
September 7, 2017
When to Use Stable vs Transiently Humanized I/O Models
As immunotherapeutics continue to dominate oncology headlines and research, more preclinical studies are requiring ...
LEARN MORE
September 5, 2017
Treatment Approaches for EGFR-Mutated Lung Cancer
Each year, around 140,000 people worldwide (15,000 in the United States alone) are diagnosed with epidermal growth ...
LEARN MORE
August 29, 2017
OX40 Agonists: Boosting Cancer Immunotherapy
Following our recent post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take ...
LEARN MORE
August 24, 2017
Mouse Allograft Models: A GEMM-Derived Efficacy Testing Platform
Genetically engineered mouse models (GEMM) were reviewed in a recent post, as immunocompetent, murine immunity models for immuno-oncology assays. While highly useful for monitoring cancer progression and mechanism of action studies, the spontaneous nature of GEMM tumors makes them complex and costly models for efficacy studies.
LEARN MORE
August 22, 2017
The Beginners Guide to Neoantigens and Immuno-Oncology Studies
\Neoantigens are mutation associated antigens that arise from nonsynonomous somatic variations acquired in tumors ...
LEARN MORE
August 15, 2017
Genetically Engineered Mouse Models (GEMM) for I/O Studies
Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ...
LEARN MORE
August 10, 2017
Tumor Necrosis Factor Superfamily of Ligands and Receptors 101
Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated ...
LEARN MORE
August 8, 2017
Syngeneic Tumor Mouse Models: The Pros and Cons
Immunotherapeutics are bringing remarkable survival rates for certain cancer patients, but they are also bringing some remarkable challenges for oncology drug developers. Evaluating immunomodulatory agents is more complex than assessing “common” chemotherapeutics or targeted agents. It requires preclinical models with an intact immune system (or at least ...
LEARN MORE
August 3, 2017
How Patient Derived Tumor Grafts (PDX) Accelerate Early Drug Development
× Over the year’s cancer research and drug development have moved from developing “simple” chemotherapies which stop ...
LEARN MORE
July 25, 2017
Precision Medicine: First Multi-Agent Next-Generation Sequencing Companion Diagnostic Test Approved by the FDA
Following our recent blog covering the first US FDA approval for a cancer treatment based on a biomarker regardless of ...
LEARN MORE
July 20, 2017
Overcoming the Tumor Microenvironment and Heterogeneity to Improve Preclinical Response
It is well known that the tumor microenvironment is quite complex to model preclinically. A major challenge we face is ...
LEARN MORE
July 18, 2017
Overcoming Acquired Resistance with PDX
Targeted therapies have been very successful in cancer treatment. Approved for a range of targets across many cancer ...
LEARN MORE